Abstract:The diffuse large B cell lymphoma (DLBCL) is the most common adult non-hodgkin's lymphoma. At present, rituximab in combination with CHOP program has significantly improved the prognosis of DLBCL, and about 50% of the DLBCL can be cured. However, due to the heterogeneity of the tumor, the refractory and relapsed DLBCL is still lack of effective treatment methods. With the application of gene expression profile (GEP) and the thorough research of the activation of lymphoma cells signal way, a lot of potential therapeutic targets are found.

Key words:Lymphoma, large B-cell, diffuse,Molecular targeted therapy